Autosomal dominant polycystic kidney disease: updated perspectives.

Rastogi, Anjay; Ameen, Khalid Mohammed; Al-Baghdadi, Maha; Shaffer, Kelly; Nobakht, Niloofar; Kamgar, Mohammad; Lerma, Edgar V

Rastogi, Anjay; Ameen, Khalid Mohammed; Al-Baghdadi, Maha; Shaffer, Kelly; Nobakht, Niloofar; Kamgar, Mohammad; Lerma, Edgar V.

Afiliação

Rastogi A; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Ameen KM; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Al-Baghdadi M; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Shaffer K; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Nobakht N; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Kamgar M; Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA.
Lerma EV; Department of Medicine, Divison of Nephrology, University of Illinois at Chicago/Advocate Christ Medical Center, Section of Nephrology, Oak Lawn, IL, USA.

Ther Clin Risk Manag ; 15: 1041-1052, 2019.

Article em En | MEDLINE | ID: mdl-31692482

Palavras-chave

chronic kidney disease; hypertension; metformin; tolvaptan; total kidney volume; vasopressin receptor antagonist

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ther Clin Risk Manag Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Nova Zelândia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google